On the Latest in Organoid Technology—Robert Vries, PhD—Hubrecht Organoid Technology (HUB)

In recent years, interest in organoid technology has exploded. More than ever before, scientists, researchers, and the public at large are beginning to appreciate the value that organoids can contribute to the understanding and clinical treatment of diseases, as well as drug development.

In 2009, the first-ever paper on this technology was published, and on today's episode, CEO of Hubrecht Organoid Technology (HUB) in the Netherlands, Robert Vries, PhD dives into the details and complexity of how it's grown since then. He explores with us the different types and functions of organoids, how they are made, and where this field of research is headed in the near future.

Interested in the details of all this and more? Tune in to discover:

• Why mimicking a cancer tumor is virtually impossible without the use of adult stem cells
• How organoid technology could change the gold standard in drug development and research in toxicology
• How induced pluripotent stem cells (iPSCs) differ from adult stem cells

For more information, check out https://hub4organoids.eu/.